Broad-spectrum RNA virus targets

Broad-spectrum RNA virus targets" is a conceptual category describing viral and host factors that, if inhibited or modulated, have the potential to suppress replication or infection of multiple RNA virus families[1][3][5]. The term encompasses diverse molecular targets, including: - Viral proteins (e.g., RNA-dependent RNA polymerase, viral proteases) - Viral RNA structures (e.g., highly conserved genomic elements) - Host factors co-opted by viruses (e.g., numb-associated kinases, lipid metabolism enzymes, membrane trafficking proteins) - Host innate immune sensors (e.g., TLRs, STING pathway components) These are not individual entities but groups of molecules that are functionally broad targets for antiviral strategies. Drugs developed to act on such broad-spectrum targets include nucleoside analogues (e.g., remdesivir, molnupiravir), kinase inhibitors (e.g., sunitinib-erlotinib combos), and immunomodulatory molecules (e.g., STING agonists)[1][3][5]. The main therapeutic goal with broad-spectrum RNA virus targeting is to generate antiviral agents effective against multiple, taxonomically distinct RNA viruses—especially important for pandemic preparedness[1][5]. Novel approaches also include programmable oligonucleotide therapeutics that aim to disable highly conserved, functionally essential viral RNA structures[1]. Because this is a category and not a specific molecule, structured information as requested does not apply directly. Summary: "Broad-spectrum RNA virus targets" is not a valid target for structured molecular annotation; it is an umbrella term for multiple candidate targets (including viral polymerase, N-glycans on viral glycoproteins, host kinases, and immune receptors) relevant for broad-spectrum antiviral drug development[1][2][3][4][5].

Other names

Broad-spectrum antiviral targetsPan-RNA virus targets